Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865274 | 0.84 | HMGCR (0.38) | HMGCRCHRM1TBXA2RADRA1ATSHR | |
| SCHEMBL12104274 | 0.71 | ALDH1A1 (0.42) | PKML3MBTL1GAAALDH1A1 | |
| SCHEMBL14119082 | 0.68 | HSD11B1 (0.37) | PKMALDH1A1 | |
| SCHEMBL17061032 | 0.68 | TET2 (0.43) | ALDH1A1 | |
| SCHEMBL5973594 | 0.67 | POLB (0.63) | POLBGAATSHRALDH1A1 | |
| SCHEMBL6864589 | 0.66 | ALDH1A1 (0.37) | POLBTSHRALDH1A1 | |
| SCHEMBL6865696 | 0.66 | POLB (0.68) | POLBGAATSHRALDH1A1 | |
| SCHEMBL18844971 | 0.66 | SMN1; SMN2 (0.38) | TSHRALDH1A1 | |
| SCHEMBL13952908 | 0.64 | ALDH1A1 (0.33) | TSHRALDH1A1 | |
| SCHEMBL14118984 | 0.64 | KMT2A (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6803170-B2 | MIXTURE CONTAINING ACID GENERATOR | SEMICONDUCTOR LEADING EDGE TECHNOLOGIES, INC. (JP) | 2004-10-12 | — | — | US | claimed |
| EP-1179749-B1 | Resist composition and method for manufacturing semiconductor device using the resist composition | SEMICONDUCTOR LEADING EDGE TEC (JP) | 2003-10-08 | — | — | EP | claimed |
| US-20020022193-A1 | Resist composition and method for manufacturing semiconductor device using the resist composition | SEMICONDUCTOR LEADING EDGE TECHNOLOGIES, INC. | 2002-02-21 | — | — | US | claimed |
| EP-1179749-A1 | Resist composition and method for manufacturing semiconductor device using the resist composition | Semiconductor Leading Edge Technologies, Inc. (JP) | 2002-02-13 | — | — | EP | claimed |
| US-9795586-B2 | HNF4-α antagonist and use thereof | NATIONAL CANCER CENTER (KR) | 2017-10-24 | — | — | US | disclosed |
| US-9795586-B2 | HNF4-α antagonist and use thereof | NATIONAL CANCER CENTER (KR) | 2017-10-24 | — | — | US | disclosed |
| US-20170189371-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2017-07-06 | — | — | US | disclosed |
| US-20170189371-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2017-07-06 | — | — | US | disclosed |
| US-20160193238-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2016-07-07 | — | — | US | disclosed |
| US-6803170-B2 | MIXTURE CONTAINING ACID GENERATOR | SEMICONDUCTOR LEADING EDGE TECHNOLOGIES, INC. (JP) | 2004-10-12 | — | — | US | disclosed |
| EP-1179749-B1 | Resist composition and method for manufacturing semiconductor device using the resist composition | SEMICONDUCTOR LEADING EDGE TEC (JP) | 2003-10-08 | — | — | EP | disclosed |
| US-20020022193-A1 | Resist composition and method for manufacturing semiconductor device using the resist composition | SEMICONDUCTOR LEADING EDGE TECHNOLOGIES, INC. | 2002-02-21 | — | — | US | disclosed |
| EP-1179749-A1 | Resist composition and method for manufacturing semiconductor device using the resist composition | Semiconductor Leading Edge Technologies, Inc. (JP) | 2002-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189371-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | HNF4A, TCF4, WNT3A | POLB 3975/4885PKM 4733/4885L3MBTL1 2809/4885 |
| US-20160193238-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | HNF4A, TCF4, WNT3A | POLB 3975/4885PKM 4733/4885L3MBTL1 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.